Ancestim

Ancestim
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation
ATC code	L03AA12 (WHO) ;
Pharmacokinetic data
Elimination half-life	2.5 h
Excretion	renal: 90%
Identifiers
CAS Number	163545-26-4 ;
ChemSpider	none;
UNII	PYB4Q6JG41;
KEGG	D02937 ;
	(what is this?) (verify)

Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.^[1]

It is a 166 amino acid protein produced by

hematopoietic stem cells for later transplantation in certain cancer patients.^[3]

References

^ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine
S2CID 21830065
.

^ "Sobi's StemGen page". Archived from the original on 2016-07-29. Retrieved 2013-12-30.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ancestim&oldid=1198604793"

[BiovitriumDeal-1] Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine

[pmid15322567-2] S2CID 21830065
.

[3] "Sobi's StemGen page". Archived from the original on 2016-07-29. Retrieved 2013-12-30.

[1]

[3]